Lazertinib 240 mg, 80 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 240 mg, 80 mg
Reference Brands: Lazcluze (USA)
Category: Oncology Cancer Care
Lazertinib is a third‑generation EGFR tyrosine kinase inhibitor used to treat advanced or metastatic non‑small cell lung cancer (NSCLC) in adults whose tumors carry certain EGFR mutations (exon 19 deletions or exon 21 L858R substitution). It blocks abnormal EGFR signaling in cancer cells, inhibiting growth and helping shrink tumors.
Lazertinib — third party manufacturing & bulk supply
Lazertinib 240 mg, 80 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Lazertinib is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Lazertinib listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Lazertinib →Frequently Asked Questions
Lazertinib is used for the treatment of advanced or metastatic Non‑Small Cell Lung Cancer (NSCLC) in adult patients whose tumors have specific mutations in the Epidermal Growth Factor Receptor (EGFR) gene, such as exon 19 deletion or exon 21 L858R substitution. It is often prescribed in combination with Amivantamab as a first‑line chemotherapy‑free regimen for eligible patients.
Lazertinib is a small‑molecule EGFR tyrosine kinase inhibitor. It selectively and irreversibly binds to mutant EGFR proteins in cancer cells, blocking signals that promote tumor cell proliferation and survival. It is formulated with excipients suitable for oral administration.
The trade names for lazertinib include Lazcluze and Leclaza (region-specific).
Lazcluze (lazertinib) is manufactured by Janssen-Cilag, part of Johnson & Johnson.
The generic name is lazertinib.
Brand names include Lazcluze and Leclaza.
Lazertinib is manufactured in GMP-certified facilities by Janssen-Cilag for global distribution.
Related Products
Lanreotide
Strength:
60 mg, 90 mg, 120 mg
Form: Injection
Reference Brands: omatuline Depot (USA), Somatuline Autogel (USA)
View Details
Motixafortide Acetate
Strength:
1 mg/mL
Form: Injection
Reference Brands: Aphexda (USA)
View Details
Gemcitabine Hydrochloride
Strength:
200 mg, 1 g, 2 g
Form: Injection
Reference Brands: Gemzar (USA), Infugem (USA), Avgemsi (USA)
View Details
Avutometinib Potassium
Strength:
0.8 mg, 200 mg
Form: Capsules
Reference Brands: Avmapki (USA), Fakzynja (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
